Results 31 to 40 of about 4,368 (233)

More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY

European Journal of Endocrinology, 2021
Objective To report the final long-term safety and efficacy analyses of patients with acromegaly treated with pegvisomant from the ACROSTUDY. Design Global (15 countries), multicentre, non-interventional study (2004–2017).
M. Fleseriu, D. Führer-Sakel, A. J. van der Lely, L. De Marinis, T. Brue, J. van der Lans-Bussemaker, J. Hey-Hadavi, C. Camacho‐Hubner, M. Wajnrajch, S. Valluri, A. Palladino, R. Gomez, R. Salvatori   +12 more
semanticscholar   +1 more source

New opportunities for secondary drug therapy of acromegaly

Медицинский совет, 2020
Introduction. Acromegaly is a severe multi-organ disease that negatively affects the quality and life expectancy of patients. The continuing complexity of acromegaly curation is due to the multiplicity of pathomorphological variants growth hormone ...
V. S. Pronin, E. V. Pronin
doaj   +1 more source

Clinical and radiological evidence of the recurrence of reversible pegvisomant-related lipohypertrophy at the new site of injection in two women with acromegaly: a case series

Journal of Medical Case Reports, 2012
Introduction Pegvisomant-related lipohypertrophy may revert when changing the site of injection, but the lipohypertrophy may recur at the new site of injection.
Rochira Vincenzo, Zirilli Lucia, Diazzi Chiara, Romano Stefania, Carani Cesare   +4 more
doaj   +1 more source

The position of combined medical treatment in acromegaly

Archives of Endocrinology and Metabolism, 2020
Advances in combination medical treatment have offer new perspectives for acromegaly patients with persistent disease activity despite receiving the available medical monotherapies.
Eva C. Coopmans, Sebastiaan W. F. van Meyel, Aart J van der Lely, Sebastian J. C. M. M. Neggers   +3 more
doaj   +1 more source

The Concise Guide to PHARMACOLOGY 2023/24: Catalytic receptors

British Journal of Pharmacology, Volume 180, Issue S2, Page S241-S288, October 2023., 2023
The Concise Guide to PHARMACOLOGY 2023/24 is the sixth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of approximately 1800 drug targets, and nearly 6000 interactions with about 3900 ligands.
Stephen P. H. Alexander, Doriano Fabbro, Eamonn Kelly, Alistair A. Mathie, John A. Peters, Emma L. Veale, Jane F. Armstrong, Elena Faccenda, Simon D. Harding, Jamie A. Davies, Annie Beuve, Peter Brouckaert, Clare Bryant, John C. Burnett, Richard W. Farndale, Andreas Friebe, John Garthwaite, Adrian J. Hobbs, Gavin E. Jarvis, Doris Koesling, Michaela Kuhn, David MacEwan, Tom P. Monie, Lincoln R. Potter, Michael Russwurm, Harald H. H. W. Schmidt, Johannes‐Peter Stasch, Scott A. Waldman   +27 more
wiley   +1 more source

Magnetic resonance imaging as a predictor of therapeutic response to pasireotide in acromegaly

Clinical Endocrinology, Volume 99, Issue 4, Page 378-385, October 2023., 2023
Abstract Objective Hyperintensity signal in T2‐weighted magnetic resonance imaging (MRI) has been related to better therapeutic response during pasireotide treatment in acromegaly. The aim of the study was to evaluate T2 MRI signal intensity and its relation with pasireotide therapeutic effectiveness in real‐life clinical practice. Design, Patients and
Sabina Ruiz, Joan Gil, Betina Biagetti, Eva Venegas, Rosa Cámara, Rogelio Garcia‐Centeno, María‐Ángeles Gálvez, Antonio Picó, Silvia Maraver, Inmaculada González, Pablo Abellán, Pablo Trincado, Mayte Herrera, Pilar Olvera, Gemma Xifra, Ignacio Bernabeu, Guillermo Serra‐Soler, Sharona Azriel, Lourdes García, Davide Carvalho, Mireia Jordà, Elena Valassi, Josep Puig, Manel Puig‐Domingo   +23 more
wiley   +1 more source

A dominant-negative FGF1 mutant (the R50E mutant) suppresses tumorigenesis and angiogenesis. [PDF]

, 2013
Fibroblast growth factor-1 (FGF1) and FGF2 play a critical role in angiogenesis, a formation of new blood vessels from existing blood vessels. Integrins are critically involved in FGF signaling through crosstalk. We previously reported that FGF1 directly
Fujita, Masaaki, Hamada, Yoshinosuke, Kaneda, Teruya, Kawaguchi, Naomasa, Matsuura, Nariaki, Mori, Seiji, Nishikawa, Kyoko, Saegusa, Jun, Takada, Yoko K, Takada, Yoshikazu, Tran, Vu, Zhao, Min   +11 more
core   +6 more sources

Uso de lanreotida en combinación con cabergolina o pegvisomant en la práctica clínica en pacientes con acromegalia: el estudio ACROCOMB [PDF]

, 2016
[Abstract] PURPOSE: To describe real-world use of lanreotide combination therapy for acromegaly. PATIENTS AND METHODS: ACROCOMB is a retrospective observational Spanish study of patients with active acromegaly treated with lanreotide combination therapy
Bernabéu, Ignacio, Blanco, Concepción, Casany, Rosa, Cordido, Fernando, Cuatrecasas, Guillem, Fajardo, Carmen, Gálvez, María Ángeles, Lucas, Tomás, Maraver, Silvia, Marazuela, Mónica, Martín, Tomás, Paja, Miguel, Picó, Antonio, Puig-Domingo, Manuel, Resmini, Eugenia, Romero, Enrique, Soto, Alfonso, Venegas, Eva, Vílchez, Ricardo   +18 more
core   +2 more sources

Growth hormone receptor agonists and antagonists: From protein expression and purification to long‐acting formulations

Protein Science, Volume 32, Issue 9, September 2023., 2023
Abstract Recombinant human growth hormone (rhGH) and GH receptor antagonists (GHAs) are used clinically to treat a range of disorders associated with GH deficiency or hypersecretion, respectively. However, these biotherapeutics can be difficult and expensive to manufacture with multiple challenges from recombinant protein generation through to the ...
Yue Wang, Minah Kim, Chantal Buckley, Heather D. Maynard, Ries J. Langley, Jo K. Perry   +5 more
wiley   +1 more source

Combined treatment of somatostatin analogues with pegvisomant in acromegaly [PDF]

, 2016
Treatment of acromegaly with monotherapy long-acting somatostatin analogues (LA-SSA) as primary treatment or after neurosurgery can only achieve complete normalization of insulin-like growth factor I (IGF-I) in roughly 40 % of patients.
Franck, S.E. (Sanne), Lely, A-J. (Aart-Jan) van der, Muhammad, A. (Ammar), Neggers, S.J.C.M.M. (Bas)   +3 more
core   +3 more sources